上海莱士：公司创新研发项目之一的“SR604注射液”已进入Ⅱb期临床试验研究阶段

Group 1 - The company has responded to investor inquiries regarding its innovative drug projects, specifically mentioning the "SR604 injection" which is currently in Phase IIb clinical trials [2] - The SR604 injection is intended for subcutaneous administration to prevent and treat patients with Hemophilia A and B, as well as those with Factor VII deficiency [2]